Elanco Animal Health Inc Dossier
Qualitative Analysis
Business overview
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in the animal health sector, dedicated to innovating, developing, manufacturing, and marketing products and services to prevent and treat disease in farm animals (livestock) and companion animals (pets). Spun off from Eli Lilly and Company in 2018, Elanco has expanded its global footprint through major acquisitions, including Bayer Animal Health in 2020. The company operates in over 90 countries, offering a diverse portfolio of approximately 200 brands that span parasiticides, dermatology, vaccines, and therapeutics. Elanco's business is structurally divided into Pet Health (companion animals) and Farm Animal (livestock) segments, serving veterinarians, food producers, and pet owners worldwide.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive productivity and operational excellence initiative focused on cost of goods sold reduction, footprint optimization, and organizational restructuring.
Expected impact: Designed to deliver $200 million to $250 million in adjusted EBITDA savings by 2030 and drive 200 to 350 basis points of margin expansion from 2026 through 2028.
Strategic focus on scaling the 'Big 6' major innovation products (including Zenrelia and Credelio Quattro) and advancing the 'next wave' pipeline.
Expected impact: Aims to generate $1.2 billion in innovation revenue in 2026 and over $2 billion in peak sales potential from the next wave pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To advance Elanco's presence in the growing global dairy market by adding a portfolio of products that support transition cow health, well-being, and productivity, while reducing the need for antibiotics through Quorum Sensing Technology.
Financial impact: Expands Elanco's solutions for sustainability, animal welfare, and transition cow health, integrating AHV's technologies with Elanco's scientific expertise and distribution network.
Strategic Partnerships
Brings two avian metapneumovirus (aMPV) vaccines (RESPIVAC aMPV and HIPRAVIAR TRT) to the U.S. poultry market to help producers manage costly respiratory diseases.
Terms: Not disclosed
An expansion of a July 2025 licensing agreement, securing a five-year strategic supply agreement providing Neurizon with long-term access to GMP-grade monepantel manufactured by Elanco for human pharmaceutical use (specifically for ALS drug candidate NUZ-001).
Terms: Not disclosed